Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by.

Published byΑλκιππη Κουβέλης Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by."— Presentation transcript:

1 Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE.
Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. (A) Disease progression in C57Bl6/YFP-H MOG EAE mice treated for 2 weeks with IL-4 via intrathecal injection (blue; n = 5) or intranasally with IL-4 or PBS (light blue and red; n = 12 each) during the chronic phase (gray bar). (B) Representative images of horizontal sections of the YFP-labeled CST counterstained for APP, showing axonal swellings. Scale bar, 50 μm. (C) Quantification of axon swellings corrected for the analyzed area (n = 3 each group, average of three to five sections per animal). Statistical analysis was performed using two-way ANOVA for repeated measures with Bonferroni correction for clinical score and one-way ANOVA with Tukey’s multiple comparison test for quantification of axonal swellings. *P < 0.05, ***P < Christina F. Vogelaar et al., Sci Transl Med 2018;10:eaao2304 Published by AAAS

Download ppt "Fig. 7 Improvement of clinical score and axon pathology by nasal IL-4 treatment during chronic EAE. Improvement of clinical score and axon pathology by."

Similar presentations

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 6. C3 deficiency resulted in partial sparing of neuron loss in hippocampal CA3 in 16-month-old APP/PS1 mice. C3 deficiency resulted in partial sparing.

Fig. 6. C3 deficiency resulted in partial sparing of neuron loss in hippocampal CA3 in 16-month-old APP/PS1 mice. C3 deficiency resulted in partial sparing.
Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.
Fig. 1. The effect of dietary micronutrient deficiency on the configuration of a defined human gut microbiota established in gnotobiotic mice. The effect.

Fig. 1. The effect of dietary micronutrient deficiency on the configuration of a defined human gut microbiota established in gnotobiotic mice. The effect.
Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.

Fig. 1. BCAS1 expression identifies newly generated oligodendrocytes.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.
Analysis of brain and spinal cord of treated Gaa−/− mice and controls

Analysis of brain and spinal cord of treated Gaa−/− mice and controls
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 3. A circadian rhythm in fibroblast wound-healing response.

Fig. 3. A circadian rhythm in fibroblast wound-healing response.
MRSA virulence proteins cause LMC death and diminished CLV function

MRSA virulence proteins cause LMC death and diminished CLV function
Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.

Fig. 4 Infection-induced CLV dysfunction is associated with decreased LMC coverage. Infection-induced CLV dysfunction is associated with decreased LMC.
Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.

Fig. 6. Effects of CD31-NP targeting in perfused human kidneys.
Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.
Fig. 4. Specific versus nonspecific NP accumulation.

Fig. 4. Specific versus nonspecific NP accumulation.

Similar presentations

Ads by Google